Special Issue

Personalized Approaches in Bladder Cancer Treatment: A Clinical and Translational Research Perspective

Message from the Guest Editor

Recent years have seen significant advancements in bladder cancer treatment, including the introduction of immune checkpoint inhibitors (e.g., atezolizumab. pembrolizumab, and avelumab) and antibody-drug conjugates (ADCs) such as enfortumab vedotin (EV) and sacituzumab govitecan (SG). Despite these advancements, platinum-based chemotherapy drugs remain a cornerstone treatment for patients with advanced BC. Intravesical instillations of Bacillus Calmette-Guérin (BCG) remain the treatment of choice for high-grade superficial BC, including carcinoma in situ (CIS). While the efficacy of BCG therapy is substantial, with 5-year recurrence-free survival rates ranging from 50% to 70%, patients who fail BCG treatment should undergo radical cystectomy to control the cancer. Therefore, new advances in both systemic and local (intravesical) therapies are necessary. Given the growing number of available treatment options for BC, personalized or tailored therapy has become a key focus in optimizing patient outcomes. This Special Issue aims at publishing up-to-date articles covering a broad range of basic, translational, and clinical research in the field of bladder cancer.

Guest Editor

Dr. Vladimir Bilim

- 1. Department of Urology, Kameda Daiichi Hospital, Niigata City 950-0165, Japan
- 2. Division of Molecular Oncology, Department of Urology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan

Deadline for manuscript submissions

28 February 2026



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/237799

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

